KKR looks to leverage growth of biopharma royalties with HCRx
'We’re seeing a lot of capital needs not only across the therapeutic side of life sciences but also this biopharma ecosystem of all of the companies that serve these biopharma businesses,' said KKR's Ali Satvat.
26 August 2025•4 mins read
